Poseida Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-04-16: Study NCT06014762; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2022-05-05: Study NCT04960579; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2022-02-15: Study NCT05239143; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2020-02-28: Study NCT04249947; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-04-16 | NCT06014762 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Lead sponsor | Phase 1 | Active not recruiting | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (tFL); Follicular Lymphoma Grade 3B; DLBCL; DLBCL - Diffuse Large B Cell Lymphoma; DLBCL Arising From Follicular Lymphoma; DLBCL, Diffused Large B Cell Lymphoma; DLBCL NOS | 120 | 2041-03 |
| 2022-05-05 | NCT04960579 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Lead sponsor | Phase 1 | Active not recruiting | Multiple Myeloma | 275 | 2042-03 |
| 2022-02-15 | NCT05239143 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1 | Active not recruiting | Breast Cancer; Ovarian Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Renal Cell Carcinoma; Nasopharyngeal Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Cancer | 180 | 2039-04 |
| 2020-02-28 | NCT04249947 P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | Lead sponsor | Phase 1 | Terminated | Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor | 40 | 2024-09-30 |
| 2018-10-29 | NCT03741127 Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | Lead sponsor | Phase 1 | Active not recruiting | Multiple Myeloma | 100 | 2032-11 |
| 2017-09-20 | NCT03288493 P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Multiple Myeloma | 105 | 2022-04-27 |